



**INTERIM FINANCIAL INFORMATION FOR THE THREE-MONTH PERIOD ENDED
JANUARY 31, 2008.**

Vaudreuil-Dorion, Quebec, March 28, 2008

Immunotec Inc. (TSX-V: IMM) (the "Company" or "Immunotec"), is engaged primarily in the development, manufacturing and marketing of health and wellness products which are classified as nutraceuticals, dietary supplements, or natural health products. These products are distributed and sold in Canada and the United States through a network marketing system and in other countries under distributorship agreements.

Currently, approximately 53% of the network sales are in Canada and 38% are in the U.S., with the remainder through export to other International Markets. By individual markets and in their respective local currencies, compared to prior year, net sales in the Canadian market posted an increase of 6%, the U.S. market was slightly ahead of the prior year and International Markets realized a 69% increase, albeit on a small base.

Consolidated in Canadian dollars for the first quarter ended January 31, 2008, the Company realized net sales of \$8,644,415 compared to \$8,655,143 in 2007, a decrease of \$10,728. This variation included an unfavourable foreign exchange effect of approximately \$661,000 due to the stronger Canadian dollar relative to the comparable period in 2007.

SELECTED CONSOLIDATED FINANCIAL INTERIM INFORMATION

	Q1 January 31,2008 (\$) unaudited	Q1 January 31, 2007 (\$) unaudited
Net Sales	8,644,415	8,655,143
Cost of Sales	1,639,607	1,397,241
Sales Incentives	3,542,210	3,642,096
Selling, General and Administrative	2,897,508	2,866,147
Earnings before income taxes	565,090	749,659
Net Earnings	311,061	505,763
Net Earnings per share:		
Basic	0.004	0.008
Diluted	0.004	0.007
Weighed average number of common shares outstanding:		
Basic	69,994,300	62,869,951
Diluted	69,994,300	68,325,721

	As at January 31, 2008 (\$) <u>unaudited</u>	As at October 31, 2007 (\$) <u>audited</u>
<u>ASSETS:</u>		
Cash	4,859,061	3,874,558
Accounts receivable	594,131	505,366
Other current Assets	<u>3,676,669</u>	<u>3,728,109</u>
Total current Assets	<u>9,129,861</u>	<u>8,108,033</u>
Other Assets	11,995,276	12,246,573
TOTAL ASSETS	<u>21,125,137</u>	<u>20,354,606</u>
<u>LIABILITIES:</u>		
Current Liabilities	3,833,414	3,475,800
Long Term Liabilities	283,682	393,600
TOTAL LIABILITIES	<u>4,117,096</u>	<u>3,869,400</u>
<u>SHAREHOLDERS' EQUITY:</u>		
Share Capital	3,465,548	3,465,548
Other Equity-Stock Options	948,190	736,416
Contributed surplus	11,326,406	11,326,406
Retained Earnings	<u>1,267,897</u>	<u>956,836</u>
TOTAL SHAREHOLDERS' EQUITY	<u>17,008,041</u>	<u>16,485,206</u>

OPERATING RESULTS FOR THE FIRST QUARTER ENDED JANUARY 31, 2008

Net earnings were \$311,061 (\$0.004 per share) for the first quarter ending January 31, 2008 compared to \$505,763 (\$0.008 per share) for the comparable period in 2007. The decrease of the net earnings is mainly attributable due to the increase in stock option compensation expense and to lower product gross margins from product/market mix, which was partially offset by a gain in foreign exchange variation.

FINANCIAL SITUATION AND LIQUIDITY

As at January 31, 2008, the Company had a cash position of \$4,859,061 compared to \$1,879,069 as at January 31, 2007. The Company believes that cash requirements in the ordinary course of business for next year can be met with its available cash, cash generated from its operating activities and the reduction of income tax payments caused by the realization of prior years income tax losses. If required, the Company has access to operating credit facilities of \$2,000,000 at its bank's prime rate plus 1/2 %. The credit facilities were not drawn upon to date.

As at January 31, 2008, the Company shows a working capital of \$5,296,447 for a ratio of 2.38 compared to a working capital of \$2,640,049 with a ratio of 1.44 as at January 31, 2007. This improvement is mainly attributable to the fact that the Company reinvests the majority of the funds generated by the operations.

HIGHLIGHTS

On November 5, 2007, Mr. James A. Northrop was appointed President and Chief Executive Officer replacing Mr. Charles Roberts who retired. Mr. Roberts continues as an active member of the Board and as co-founder of the Company. Mr. Northrop has impressive experience in the direct selling industry and is a seasoned chief executive with a record of success in rapid growth situations.

On November 13, 2007, the Company achieved a significant milestone by receiving regulatory approval from Health Canada to market HMS 90® / IMMUNOCAL® with the following health claim: "a natural source of the glutathione precursor cysteine for the maintenance of a strong immune system."

On January 17, 2008, the Company announced the successful completion of a multi-center randomized, double-blind clinical trial on cancer-related weight loss (cachexia) in lung cancer patients which was performed in collaboration with various Canadian clinical centers. A second trial has been initiated to confirm the results.

In the last two quarters, the Company's total net sales showed increases of 3.0% and 7.5%, respectively, (excluding the foreign exchange impact), compared to the corresponding periods in 2007. This positive trend represents a reversal of sales declines the Company had expressed in the prior six quarters and supports the beneficial impact of the sales and marketing initiatives implemented in 2007.

OUTLOOK

Immunotec benefits from a solid balance sheet, skilled and motivated employees, well established suppliers, repeat customers and a dedicated network of distributors. Since last year the management implemented new measures and sales and marketing initiatives and it believes that these measures will help increase sales during the present and following years.

Management is of the opinion that its investment in current research in such areas as cancer cachexia, prostate health, aging and aging related conditions will enable Immunotec to produce and bring to market more value added products which will continue to differentiate its products from competing products.

Immunotec, following recommendations from its Product Development Committee, is constantly developing new products that are appropriate for its health and wellness markets.

ABOUT IMMUNOTEC

Immunotec operates out of a 37,000 square foot facility located in Vaudreuil-Dorion, Quebec, Canada as well as a manufacturing facility located in Blainville, Quebec, Canada and a distribution centre located in Swanton, Vermont, USA. Immunotec is engaged primarily in the development and marketing of dietary supplements, food, vitamins, personal care products and natural health products, some of which are manufactured on its behalf by third parties. Immunotec's products are distributed and sold in Canada and the United States through a network marketing system and in other countries under distributorship agreements.

The TSX Venture does not accept responsibility for the adequacy or accuracy of this release.

Contact: Richard Patte, CA, Executive Vice-President and Chief Financial Officer.
tel.: (450) 510-4445